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This research suggests the development of a universal 
protocol for prophylactic administration of Pitocin in the 
third stage of labor in order to prevent postpartum 
hemorrhage and decrease maternal mortality rates (MMR). 
The United States MMR has increased from 16.9 per 100,000 
live births in 1990 to 26.4 per 100,000 live births in 2015 
(Zelop, 2018, p. 8). It is imperative that health care providers 
intervene at the third stage of labor to decrease the risk of 
death and complications. 
Abstract
Figure 1
Pitocin Molecular Build
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Pitocin is the synthetic form of oxytocin and is used to 
stimulate uterine smooth muscle to contract the uterus in 
order to induce labor or to control bleeding postpartum 
(Davis Drug Guide, 2020). It is a vasopressor and 
antidiuretic;therefore, it is important to monitor the patient's 
blood pressure throughout administration  (Davis Drug 
Guide, 2020). 
Research suggests that the administration of prophylactic 
Pitocin in the third stage of labor intravenously or 
intramuscularly decreases the risk of postpartum hemorrhage 
by 40% (Cássia de Oliveira & Barbosa-Davim, 2019). The 
FDA (2020) recommends 40 units/ in 1,000 mL of lactated 
ringer's intravenously (IV) or 10 units of Pitocin 
intramuscular (IM) administration in the event that the 
patient is showing signs of PPH. However, there is no 
protocol for routine use in the third stage of labor and it is 
often up to physician discretion. The Queensland Clinic 
(2019), recommends the prophylactic administration of 
Pitocin on all pts beginning at 10 international units via IM 
injection for a vaginal birth and 5 international units via IV 
for a cesarean section. 
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Source: (Zelop, 2019, p. 8).
Overall, there is a lack of research available addressing the 
significant rise of maternal morbidity in the United States. It 
is alarming that such a well developed country has such high 
maternal mortality rates, Therefore, more research needs to 
be done in order to provide quality and safe care of all 
laboring patients. In regards to future research, there needs to 
be more studies done in order to provide for all patient 
populations; for example,“current clinical practice guidelines 
for third stage oxytocin administration do not distinguish 
between women with prior oxytocin exposure and those 
without” (Bischoff, K., et al., p. 10, 2017). It’s 
“recommended that hospitals establish protocols to enable an 
optimal response to changes in maternal vital signs and 
clinical conditions. These protocols should be tested in drills, 
and systems problems that interfere with care should be fixed 
through their continual refinement,” (Evesen, A., Anderson, 
J., & Fontaine, P., p. 447, 2017).
Recommendations for Future Research
The title question was constructed using the PICO method. 
The “P” stands for the population of participants of interest 
in the clinical setting; pregnant and laboring women is the 
population for the purposes of this research. The “I” 
represents the intervention needed for practice and for this 
research project “prophylactic Pitocin administration 
protocols”. Within the PICO question the “C” stands for 
comparisons of interventions to determine the best 
intervention for practice. In this research, the “C” stands for 
no administration of Pitocin. Finally, the “O” stands for 
outcomes needed for practice and ways to measure the 
outcomes in practice. For the purposes of this research, “O” 
represents the decreased risk of postpartum hemorrhage and 
maternal deaths. 
This research advises the prophylactic administration of 
Pitocin in order to prevent or decrease the risk of postpartum 
hemorrhages. Early intervention will decrease the MMR as 
44.4% of maternal deaths occur in the 6 week time period 
after delivery of the fetus. (Zelop, 2018). The health system 
needs to be more proactive by “encompassing antepartum, 
intrapartum, postpartum and interconception care” (Zelop, 
2018, p. 11). On a global scale, an average of one woman 
dies every 4 minutes as a result of postpartum hemorrhage 
complications (Moncneff, 2018). A postpartum hemorrhage 
is defined as a blood loss of ≥500mL in a vaginal delivery or 
a blood loss of  ≥1,000mL in a cesarean delivery (Perry, S. 
E., et al., 2018).
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Sources
Overall, this research aimed to reveal that “there is a global 
concern to implement health actions that can adequately 
prevent and treat the complications of PPH, which in many 
cases causes maternal morbidity and mortality,” (Cássia de 
Oliveira & Barbosa-Davim, 2019). Prophylactic Pitocin is 
crucial in all patients in order to prevent and treat postpartum 
hemorrhages. Research show that “For clinical practice, 
providers might benefit from knowing 10 IU of IV bolus is a 
good, safe option for women after vaginal delivery,” 
(Charles, D. et al., p. 6, 2019). 
Conclusion
In a study done that compares the blood loss and incidence of 
postpartum hemorrhage (PPH), there was a control group and 
an experimental group used. The control group did not 
receive the routine use of prophylactic oxytocin (RUPO), 
while the experimental group, or the RUPO group, did. The 
study shows that “the incidence of PPH ≥ 1,000 mL was also 
significantly reduced from 14.0% in the control group to 
6.1% in the RUPO group, despite the women in the RUPO 
group being more obese and having a longer first stage of 
labor, both of which are risk factors of excessive bleeding,” 
(Kuzume, Akiko, et al., para 16, 2017). 
Table 2
Risk Factors of PPH: The 4 Ts
Source: (Moncrieff, 2018, p. 224).
